Compare DLPN & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | LEXX |
|---|---|---|
| Founded | 1996 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 22.7M |
| IPO Year | N/A | N/A |
| Metric | DLPN | LEXX |
|---|---|---|
| Price | $1.65 | $1.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 34.5K | ★ 185.4K |
| Earning Date | 11-12-2025 | 01-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,371,115.00 | $705,923.00 |
| Revenue This Year | $9.05 | $13.35 |
| Revenue Next Year | $15.42 | $78.83 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 3.86 | ★ 52.05 |
| 52 Week Low | $0.75 | $0.77 |
| 52 Week High | $1.88 | $2.85 |
| Indicator | DLPN | LEXX |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 50.82 |
| Support Level | $1.60 | $1.00 |
| Resistance Level | $1.84 | $1.15 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 31.58 | 41.49 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.